CJC-1295 + Ipamorelin

Why people combine them

Discussed as a GHRH-analogue plus GH-secretagogue pairing intended to stimulate GH release through two pathways at once — the “synthetic GH axis” pairing. The rationale appears in vendor and community material; the pharmacology of each pathway is real, but the pairing itself was not studied in the indexed literature.

Evidence for the combination

No direct combination study is currently indexed by Therapept. What exists is evidence for each component separately — which is not evidence that combining them adds anything.

Evidence for each component

• CJC-1295 — Human interventional evidence exists for the DAC form (GH/IGF-I elevation, healthy adults, placebo-controlled). Development did not produce an approved drug; a later-trial death is recorded in reviews as a development event.
• Ipamorelin — Human PK/PD evidence in volunteers; selectivity profile from preclinical work. On FDA's active 503B Category 2 compounding-risk table.

Commonly reported dosing and protocols

Displayed source by source. Therapept does not compose these into a recommended protocol.

• COMMUNITYReddit / forums (recurring)

  Posts commonly describe blended subcutaneous injections on daily or five-days-on/two-off schedules, with CJC-1295 quoted per-µg and ipamorelin per-µg amounts that vary widely between threads.

  Reported practice with no primary-source anchor; quantities are not reproduced here as a protocol.

  Checked 17 September 2026 · Community sources — see the dosing reference for limitations

Potential overlap and concerns

• CJC-1295's FDA compounding entry references serious adverse events (increased heart rate, systemic vasodilatory reaction); ipamorelin sits on the active 503B Category 2 table.
• Both are WADA-prohibited (S2.2.4, GHRH analogues and GH secretagogues).
• The human CJC-1295 evidence concerns the DAC molecule; most community stacks refer to the non-DAC fragment, which lacks that evidence.